Trial Identifiers
Use the hyperlinks, where available to access additional clinical trial information.
Trial sponsor
Novartis Pharmaceuticals
Scientific Title
A randomised, open label, multicenter phase II study evaluating the efficacy and safety of capmatinib (INC280) plus pembrolizumb versus pembrolizumab alone as a first line treatment for locally advanced or metastatic non-small cell lung cancer with PD-L1 ≥ 50%